Company · AMGN
Amgen
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
40
31 still marketed
Novel approvals
20
Approvals since 2021
41
Originals and new uses
Phase 3 trials
311
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Pavblu approved Oct 22, 2026
- Repatha new use OrphanOct 9, 2026
- Imdelltra new use Priority reviewOrphanNov 19, 2025
- Otezla approved Aug 29, 2025
- Otezla approved OrphanAug 29, 2025
- Otezla new use OrphanJul 23, 2025
- Prolia new use May 22, 2025
- Kyprolis new use Priority reviewOrphanMay 22, 2025
- Amjevita new use May 20, 2025
- Amjevita new use Apr 7, 2025
Drugs in development (18)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- AmrubicinJapan onlyPhase 34 trials
Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)
- DazodalibepVIB 4920, MEDI 4920Phase 33 trials
Amgen · Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome
- OlpasiranAMG 890Phase 33 trials
Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease
- RocatinlimabAMG 451Phase 33 trials
Amgen · Atopic Dermatitis
- ABP 206Phase 32 trials
Amgen · Melanoma
- ABP 234Phase 32 trials
Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- BisphosphonatePhase 32 trials
Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta
- XaluritamigAMG 509Phase 32 trials
Amgen · Metastatic Castration-resistant Prostate Cancer
- ABP 692Phase 31 trial
Amgen · Relapsing-remitting Multiple Sclerosis (RRMS)
- ABP 938Phase 31 trial
Amgen · Neovascular Age-related Macular Degeneration, nAMD
- BemarituzumabPhase 31 trial
Amgen · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- EU-authorized NivolumabPhase 31 trial
Amgen · Melanoma
- FDA-licensed NivolumabPhase 31 trial
Amgen · Melanoma
- AnvumetostatAMG 193Phase 23 trials
Amgen · Advanced MTAP-null Solid Tumors, MTAP-deleted NSCLC, MTAP-null Non-Small-Cell Lung Cancer
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- DaxdilimabHZN-7734Phase 21 trial
Amgen · Idiopathic Inflammatory Myositis
- IDE397Phase 21 trial
Amgen · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
Recruiting Phase 3 trials
Largest first.
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular EventsPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07136012 · 11,000 participants (planned) · Start Aug 22, 2025 · Primary completion Oct 20, 2031
Drug: Olpasiran; Placebo · For: Cardiovascular Disease
Sites: Alexander City, Alabama; Birmingham, Alabama; Daphne, Alabama · 261 sites in all
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07037459 · 5,056 participants (planned) · Start Jun 25, 2025 · Primary completion Jun 30, 2028
Drug: Maridebart cafraglutide; Placebo · For: Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity
Sites: Birmingham, Alabama; Dothan, Alabama; Fairhope, Alabama · 686 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684235 · 3,200 participants (planned) · Start Jul 23, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart cafraglutide; Placebo · For: Obesity; Overweight
Sites: Anniston, Alabama; Daphne, Alabama; Mobile, Alabama · 92 sites in all
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07866066 · 1,300 participants (planned) · Start Oct 16, 2026 · Primary completion Sep 6, 2028
Drug: Maridebart cafraglutide; Semaglutide · For: Diabetes Mellitus, Type 2
Sites: San Diego, California; Miami, Florida; Miami Lakes, Florida · 8 sites in all
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07684144 · 950 participants (planned) · Start Jul 29, 2026 · Primary completion Dec 26, 2027
Drug: Maridebart Cafraglutide; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Canoga Park, California; Cerritos, California · 45 sites in all
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06747949 · 844 participants (planned) · Start Feb 25, 2025 · Primary completion Dec 11, 2029
Drug: Dazodalibep · For: Sjögren's Syndrome
Sites: Avondale, Arizona; Flagstaff, Arizona; Gilbert, Arizona · 174 sites in all
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07213674 · 750 participants (planned) · Start Nov 28, 2025 · Primary completion Jan 7, 2030
Drug: Xaluritamig; Abiraterone acetate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Goodyear, Arizona; Tucson, Arizona; Duarte, California · 159 sites in all
AmgenAmgen (AMGN)
NCT05920356 · 750 participants (planned) · Start Nov 16, 2023 · Primary completion Jun 30, 2027
Drug: Sotorasib; Pembrolizumab · For: Non-Small Cell Lung Cancer (NSCLC)
Sites: Santa Barbara, California; Newark, Delaware; Coral Springs, Florida · 418 sites in all
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06252649 · 450 participants (planned) · Start Jul 17, 2024 · Primary completion Sep 25, 2028
Drug: FOLFIRI Regimen; Sotorasib and 2 more · For: Metastatic Colorectal Cancer
Sites: Chandler, Arizona; Fullerton, California; Long Beach, California · 291 sites in all
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07293260 · 406 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 15, 2028
Drug: Olpasiran; Placebo · For: Cardiovascular Disease
Sites: Bridgeport, Connecticut; Jacksonville, Florida; Overland Park, Kansas · 40 sites in all
Marketed drugs (31)
Newest FDA action first.
- Kanjinti Trastuzumab-Anns · 2019
- Amjevita Adalimumab-Atto · 2016
- Pavblu Aflibercept-Ayyh · 2026
- Repatha Evolocumab · 2021
- Riabni Rituximab-Arrx · 2020
- Tepezza Teprotumumab-Trbw · 2020
- Imdelltra Tarlatamab-Dlle · 2024
- Krystexxa Pegloticase · 2010
- Neulasta Pegfilgrastim · 2002
- Neupogen Filgrastim · 1991
- Bkemv Eculizumab-Aeeb · 2024
- Prolia Denosumab · 2010
- Wezlana Ustekinumab-Auub · 2023
- Wezlana Ustekinumab-Auub · 2023
- Otezla Apremilast · 2014
- Blincyto Blinatumomab · 2014
- Otezla Apremilast · 2025
- Avsola Infliximab-Axxq · 2019
- Aimovig Erenumab-Aooe · 2018
- Kyprolis Carfilzomib · 2012
- Nplate Romiplostim · 2008
- Vectibix Panitumumab · 2006
- Lumakras Sotorasib · 2021
- Epogen/Procrit Epoetin Alfa · 1989
- Aranesp Darbepoetin Alfa · 2001
- Mvasi Bevacizumab-Awwb · 2017
- Procysbi Cysteamine Bitartrate · 2020
- Procysbi Cysteamine Bitartrate · 2013
- Ravicti Glycerol Phenylbutyrate · 2013
- Evenity Romosozumab-Aqqg · 2019
- Actimmune Interferon Gamma-1b · 1999
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.